Liver Disease Treatment Market Size Analysis Report - Market Share, Forecast Trends and Outlook (2025-2034)
Description
The liver disease treatment market was valued at USD 20.14 Billion in 2024 , driven by the increasing prevalence of liver disease across the 8 major markets. The market is expected to grow at a CAGR of 10.40% during the forecast period of 2025-2034, with the values likely to reach USD 54.17 Billion by 2034.
Liver Disease Treatment Market Overview
A liver disease directly affects the liver and progresses slowly unlike acute liver failure. Untreated liver disease can result in liver cancer or liver failure. Treatments for liver disease can include antiviral drugs to treat hepatitis, steroids for managing liver inflammation, and others. The increasing cases of liver disease due to factors such as obesity, viral infections, and alcohol consumption is a major growth driver of the market. Further, the rising development of novel therapeutics such as immune modulators and gene therapies that offer better clinical benefits are expected to augment the market demand. Moreover, improvements in diagnostic tools including imaging techniques and biomarker tests for diagnosing and monitoring liver diseases is also contributing to the market growth.
Liver Disease Treatment Market Growth Drivers
Rising Prevalence of Liver Diseases to Drive Market Growth
Recent data reveals that over 100 million individuals in the United States are affected by liver or hepatic disease. It is reported that 4.5 million adults have been diagnosed with liver disease. However, around 80 to 100 million U.S. adults are estimated to have undiagnosed fatty liver disease in varying stages. The increasing prevalence of liver diseases is expected to drive the demand for effective treatment. Additionally, the growing geriatric population, which is more prone to liver diseases, is poised to contribute to the market demand.
Liver Disease Treatment Market Trends
The market is witnessing several trends and developments to improve the current scenario across the 8 major markets. Some of the notable trends are as follows:
Increased Public Health Initiatives to Impact the Market Landscape
The market is witnessing increased awareness campaigns and screening programs by global health organizations and governments in order to promote early diagnosis and treatment of liver disease. Such public health initiatives, especially for diseases like hepatitis B and C, are encouraging more people to seek treatment. These factors are likely to influence the market landscape signficantly.
Surge in FDA Approval to Meet Rising Liver Disease Treatment Market Demand
In March 2024 , Rezdiffra™ developed by biopharma company Madrigal Pharmaceuticals, Inc. became the first and only FDA-approved treatment for noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis. Moreover, in February 2024 , GSK plc's investigational candidate bepirovirsen received Fast Track designation for the treatment of chronic hepatitis B (CHB) by the FDA. The surge in the approval of innovative drugs for the treatment of liver disease, supported by the presence of a favorable regulatory environment is a major trend, poised to amplify the market demand in coming years.
Advancements in Diagnostic Technologies Likely to Boost Liver Disease Treatment Market Size
The rising advancements in imaging technologies, such as transient elastography (FibroScan), magnetic resonance elastography (MRE), and multiparametric MRI are experiencing popularity among patients due to their non-invasive assessment of liver fibrosis and steatosis. The increasing availability of non-invasive diagnostic tools is anticipated to contribute to the market growth.
Shift Towards Combination Therapies is Poised to Elevate the Liver Disease Treatment Market Value
There is a growing demand for combination therapies in the market as these treatment approaches often result in improved clinical outcomes. For instance, in cases of Hepatitis C and NASH, the combination of antiviral agents with other drug classes is seen to increase efficacy and reduce drug resistance. Thus, the rising preference for combination therapies is set to shape the market dynamics in the forecast period.
Liver Disease Treatment Market Segmentation
"The Expert Market Research report titled “Liver Disease Treatment Market Report and Forecast 2025-2034" offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment Type:
Market Segmentation Based on Treatment Type is Anticipated to Witness Substantial Growth
Based on the treatment type, the market is segmented into antiviral drugs, immunosuppressants, vaccines, immunoglobulins, corticosteroids, targeted therapy, and chemotherapy, among others. The antiviral drugs segment covers a significant market share due to the high prevalence of viral hepatitis such as hepatitis B and C. The development of new antiviral agents with higher efficacy and better safety profiles further boosts the market share. Moreover, the chronic nature of hepatitis B and C, if not treated effectively, necessitates long-term antiviral therapy, which is likely to augment the market demand in the forecast period.
Liver Disease Treatment Market Analysis by Region
Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States dominates the market share due to the considerable burden of liver diseases, the presence of advanced healthcare infrastructure, and a strong focus on research and development activities in the region. The high healthcare expenditure allows access to innovative therapies and also supports the development of new treatments in the region. Moreover, the presence of key players in the United States that are engaged in developing antiviral and targeted therapies for liver diseases is expected to bolster the market growth.
Leading Players in the Liver Disease Treatment Market
The key features of the market report comprise the patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Abbott Laboratories
American multinational medical devices and health care company Abbott Laboratories is a prominent player in the market. Its drug SILLIVER® (Silymarin) is indicated for the treatment of liver diseases such as liver cirrhosis, acute hepatitis, and toxic metabolic liver damage. Silymarin is also known to protect against liver damage by general anesthesia.
Bristol-Myers Squibb Company
Headquartered in Princeton, New Jersey, Bristol-Myers Squibb is widely recognized for its innovative treatments including therapies for liver diseases. One of its key medications is the FDA-approved Daklinza (daclatasvir ) taken in combination with sofosbuvir for the treatment of chronic hepatitis C genotype 3.
Gilead Sciences
California-based Gilead Sciences is an American biopharmaceutical company that specializes in the development of antiviral therapies, particularly for liver diseases. Gilead actively collaborates with research institutions and healthcare organizations to boost its research capabilities and expand its portfolio in liver disease treatment.
GlaxoSmithKline PLC
Leading biopharma company GlaxoSmithKline PLC is headquartered in Brentford, United Kingdom, and focuses on the development of vaccine development, antiviral therapies, and innovative treatment approaches for chronic liver conditions.
Other key players in the market include Astellas Pharma Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi AG, AbbVie Inc., and Pfizer Inc.
Key Questions Answered in the Liver Disease Treatment Market Report
Non-alcoholic Fatty Liver Disease (NAFLD) Epidemiology Forecast
Liver Disease Treatment Market Overview
A liver disease directly affects the liver and progresses slowly unlike acute liver failure. Untreated liver disease can result in liver cancer or liver failure. Treatments for liver disease can include antiviral drugs to treat hepatitis, steroids for managing liver inflammation, and others. The increasing cases of liver disease due to factors such as obesity, viral infections, and alcohol consumption is a major growth driver of the market. Further, the rising development of novel therapeutics such as immune modulators and gene therapies that offer better clinical benefits are expected to augment the market demand. Moreover, improvements in diagnostic tools including imaging techniques and biomarker tests for diagnosing and monitoring liver diseases is also contributing to the market growth.
Liver Disease Treatment Market Growth Drivers
Rising Prevalence of Liver Diseases to Drive Market Growth
Recent data reveals that over 100 million individuals in the United States are affected by liver or hepatic disease. It is reported that 4.5 million adults have been diagnosed with liver disease. However, around 80 to 100 million U.S. adults are estimated to have undiagnosed fatty liver disease in varying stages. The increasing prevalence of liver diseases is expected to drive the demand for effective treatment. Additionally, the growing geriatric population, which is more prone to liver diseases, is poised to contribute to the market demand.
Liver Disease Treatment Market Trends
The market is witnessing several trends and developments to improve the current scenario across the 8 major markets. Some of the notable trends are as follows:
Increased Public Health Initiatives to Impact the Market Landscape
The market is witnessing increased awareness campaigns and screening programs by global health organizations and governments in order to promote early diagnosis and treatment of liver disease. Such public health initiatives, especially for diseases like hepatitis B and C, are encouraging more people to seek treatment. These factors are likely to influence the market landscape signficantly.
Surge in FDA Approval to Meet Rising Liver Disease Treatment Market Demand
In March 2024 , Rezdiffra™ developed by biopharma company Madrigal Pharmaceuticals, Inc. became the first and only FDA-approved treatment for noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis. Moreover, in February 2024 , GSK plc's investigational candidate bepirovirsen received Fast Track designation for the treatment of chronic hepatitis B (CHB) by the FDA. The surge in the approval of innovative drugs for the treatment of liver disease, supported by the presence of a favorable regulatory environment is a major trend, poised to amplify the market demand in coming years.
Advancements in Diagnostic Technologies Likely to Boost Liver Disease Treatment Market Size
The rising advancements in imaging technologies, such as transient elastography (FibroScan), magnetic resonance elastography (MRE), and multiparametric MRI are experiencing popularity among patients due to their non-invasive assessment of liver fibrosis and steatosis. The increasing availability of non-invasive diagnostic tools is anticipated to contribute to the market growth.
Shift Towards Combination Therapies is Poised to Elevate the Liver Disease Treatment Market Value
There is a growing demand for combination therapies in the market as these treatment approaches often result in improved clinical outcomes. For instance, in cases of Hepatitis C and NASH, the combination of antiviral agents with other drug classes is seen to increase efficacy and reduce drug resistance. Thus, the rising preference for combination therapies is set to shape the market dynamics in the forecast period.
Liver Disease Treatment Market Segmentation
"The Expert Market Research report titled “Liver Disease Treatment Market Report and Forecast 2025-2034" offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment Type:
- Antiviral Drugs
- Immunosuppressants
- Vaccines
- Immunoglobulins
- Corticosteroids
- Targeted Therapy
- Chemotherapy
- Others
- Hepatitis
- Autoimmune Diseases
- Non-alcoholic fatty Liver Disease
- Cancer
- Others
- Hospitals and Clinics
- Diagnostic Laboratories
- Others
- United States
- EU-4 and the United Kingdom
- Japan
- India
Market Segmentation Based on Treatment Type is Anticipated to Witness Substantial Growth
Based on the treatment type, the market is segmented into antiviral drugs, immunosuppressants, vaccines, immunoglobulins, corticosteroids, targeted therapy, and chemotherapy, among others. The antiviral drugs segment covers a significant market share due to the high prevalence of viral hepatitis such as hepatitis B and C. The development of new antiviral agents with higher efficacy and better safety profiles further boosts the market share. Moreover, the chronic nature of hepatitis B and C, if not treated effectively, necessitates long-term antiviral therapy, which is likely to augment the market demand in the forecast period.
Liver Disease Treatment Market Analysis by Region
Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States dominates the market share due to the considerable burden of liver diseases, the presence of advanced healthcare infrastructure, and a strong focus on research and development activities in the region. The high healthcare expenditure allows access to innovative therapies and also supports the development of new treatments in the region. Moreover, the presence of key players in the United States that are engaged in developing antiviral and targeted therapies for liver diseases is expected to bolster the market growth.
Leading Players in the Liver Disease Treatment Market
The key features of the market report comprise the patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Abbott Laboratories
American multinational medical devices and health care company Abbott Laboratories is a prominent player in the market. Its drug SILLIVER® (Silymarin) is indicated for the treatment of liver diseases such as liver cirrhosis, acute hepatitis, and toxic metabolic liver damage. Silymarin is also known to protect against liver damage by general anesthesia.
Bristol-Myers Squibb Company
Headquartered in Princeton, New Jersey, Bristol-Myers Squibb is widely recognized for its innovative treatments including therapies for liver diseases. One of its key medications is the FDA-approved Daklinza (daclatasvir ) taken in combination with sofosbuvir for the treatment of chronic hepatitis C genotype 3.
Gilead Sciences
California-based Gilead Sciences is an American biopharmaceutical company that specializes in the development of antiviral therapies, particularly for liver diseases. Gilead actively collaborates with research institutions and healthcare organizations to boost its research capabilities and expand its portfolio in liver disease treatment.
GlaxoSmithKline PLC
Leading biopharma company GlaxoSmithKline PLC is headquartered in Brentford, United Kingdom, and focuses on the development of vaccine development, antiviral therapies, and innovative treatment approaches for chronic liver conditions.
Other key players in the market include Astellas Pharma Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi AG, AbbVie Inc., and Pfizer Inc.
Key Questions Answered in the Liver Disease Treatment Market Report
- What was the liver disease treatment market value in 2024?
- What is the liver disease treatment market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on treatment type?
- What is the market breakup based on disease type?
- Who are the major end users in the market?
- What are the major factors aiding the liver disease treatment market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How do the prevalence and incidence of liver diseases affect the market landscape?
- What are the major liver disease treatment market trends?
- How do the improvements in diagnostic tools impact the market size?
- Which treatment type will dominate the market share?
- Which disease type is expected to have a high market value in the coming years?
- Which end user is projected to contribute to the highest market growth?
- Who are the key players involved in the liver disease treatment market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
Non-alcoholic Fatty Liver Disease (NAFLD) Epidemiology Forecast
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Liver Disease Treatment Market Overview – 8 Major Markets
- 3.1 Liver Disease Treatment Market Historical Value (2018-2024)
- 3.2 Liver Disease Treatment Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Liver Disease Treatment Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Liver Disease Treatment Market - Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 United States
- 7.1.1.2 United Kingdom
- 7.1.1.3 EU4
- 7.1.1.4 India
- 7.1.1.5 Japan
- 7.1.2 Diagnosed Cases, by Country
- 7.1.2.1 United States
- 7.1.2.2 United Kingdom
- 7.1.2.3 EU4
- 7.1.2.4 India
- 7.1.2.5 Japan
- 7.1.3 Treatment Seeking Rate, by Country
- 7.1.3.1 United States
- 7.1.3.2 United Kingdom
- 7.1.3.3 EU4
- 7.1.3.4 India
- 7.1.3.5 Japan
- 8 Liver Disease Treatment Market Landscape – 8 Major Markets
- 8.1 Liver Disease Treatment Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Liver Disease Treatment Market: Product Landscape
- 8.2.1 Analysis by Treatment Type
- 8.2.2 Analysis by Disease Type
- 9 Liver Disease Treatment Market Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Liver Disease Treatment Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Liver Disease Treatment Market Segmentation (218-2034) - 8 Major Markets
- 12.1 Liver Disease Treatment Market (2018-2034) by Treatment Type
- 12.1.1 Market Overview
- 12.1.2 Antiviral Drugs
- 12.1.3 Immunosuppressants
- 12.1.4 Vaccines
- 12.1.5 Corticosteroids
- 12.1.6 Immunoglobins
- 12.1.7 Targeted Therapy
- 12.1.8 Chemotherapy
- 12.1.9 Others
- 12.2 Liver Disease Treatment Market (2018-2034) by Disease Type
- 12.2.1 Market Overview
- 12.2.2 Hepatitis
- 12.2.3 Autoimmune Diseases
- 12.2.4 Non-alcoholic fatty Liver Disease
- 12.2.5 Cancer
- 12.2.6 Others
- 12.3 Liver Disease Treatment Market (2018-2034) by End User
- 12.3.1 Market Overview
- 12.3.2 Hospital and Clinics
- 12.3.3 Diagnostic Centers
- 12.3.4 Others
- 12.4 Liver Disease Treatment Market (2018-2034) by Region
- 12.4.1 Market Overview
- 12.4.2 United States
- 12.4.3 EU-4 and the United Kingdom
- 12.4.3.1 Germany
- 12.4.3.2 France
- 12.4.3.3 Italy
- 12.4.3.4 Spain
- 12.4.3.5 United Kingdom
- 12.4.4 Japan
- 12.4.5 India
- 13 United States Liver Disease Treatment Market (218-2034)
- 13.1 United States Liver Disease Treatment Market Historical Value (2018-2024)
- 13.2 United States Liver Disease Treatment Market Forecast Value (2025-2034)
- 13.3 United States Liver Disease Treatment Market (2018-2034) by Treatment Type
- 13.3.1 Market Overview
- 13.3.2 Antiviral Drugs
- 13.3.3 Immunosuppressants
- 13.3.4 Vaccines
- 13.3.5 Corticosteroids
- 13.3.6 Immunoglobins
- 13.3.7 Targeted Therapy
- 13.3.8 Chemotherapy
- 13.3.9 Others
- 13.4 United States Liver Disease Treatment Market (2018-2034) by Disease Type
- 13.4.1 Market Overview
- 13.4.2 Hepatitis
- 13.4.3 Autoimmune Diseases
- 13.4.4 Non-alcoholic fatty Liver Disease
- 13.4.5 Cancer
- 13.4.6 Others
- 13.5 United States Liver Disease Treatment Market (2018-2034) by End User
- 13.5.1 Market Overview
- 13.5.2 Hospital and Clinics
- 13.5.3 Diagnostic Centers
- 13.5.4 Others
- 14 EU-4 and United Kingdom Liver Disease Treatment Market (218-2034)
- 14.1 EU-4 and United Kingdom Liver Disease Treatment Market Historical Value (2018-2024)
- 14.2 EU-4 and United Kingdom Liver Disease Treatment Market Forecast Value (2025-2034)
- 14.3 EU-4 and United Kingdom Liver Disease Treatment Market (2018-2034) by Treatment Type
- 14.3.1 Market Overview
- 14.3.2 Antiviral Drugs
- 14.3.3 Immunosuppressants
- 14.3.4 Vaccines
- 14.3.5 Corticosteroids
- 14.3.6 Immunoglobins
- 14.3.7 Targeted Therapy
- 14.3.8 Chemotherapy
- 14.3.9 Others
- 14.4 EU-4 and United Kingdom Liver Disease Treatment Market (2018-2034) by Disease Type
- 14.4.1 Market Overview
- 14.4.2 Hepatitis
- 14.4.3 Autoimmune Diseases
- 14.4.4 Non-alcoholic fatty Liver Disease
- 14.4.5 Cancer
- 14.4.6 Others
- 14.5 EU-4 and United Kingdom Liver Disease Treatment Market (2018-2034) by End User
- 14.5.1 Market Overview
- 14.5.2 Hospital and Clinics
- 14.5.3 Diagnostic Centers
- 14.5.4 Others
- 15 Japan Liver Disease Treatment Market
- 15.1 Japan Liver Disease Treatment Market Historical Value (2018-2024)
- 15.2 Japan Liver Disease Treatment Market Forecast Value (2025-2034)
- 15.3 Japan Liver Disease Treatment Market (2018-2034) by Treatment Type
- 15.3.1 Market Overview
- 15.3.2 Antiviral Drugs
- 15.3.3 Immunosuppressants
- 15.3.4 Vaccines
- 15.3.5 Corticosteroids
- 15.3.6 Immunoglobins
- 15.3.7 Targeted Therapy
- 15.3.8 Chemotherapy
- 15.3.9 Others
- 15.4 Japan Liver Disease Treatment Market (2018-2034) by Disease Type
- 15.4.1 Market Overview
- 15.4.2 Hepatitis
- 15.4.3 Autoimmune Diseases
- 15.4.4 Non-alcoholic fatty Liver Disease
- 15.4.5 Cancer
- 15.4.6 Others
- 15.5 Japan Liver Disease Treatment Market (2018-2034) by End User
- 15.5.1 Market Overview
- 15.5.2 Hospital and Clinics
- 15.5.3 Diagnostic Centers
- 15.5.4 Others
- 16 India Liver Disease Treatment Market
- 16.1 India Liver Disease Treatment Market (2018-2034) Historical Value (2018-2024)
- 16.2 India Liver Disease Treatment Market (2018-2034) Forecast Value (2025-2034)
- 16.3 India Liver Disease Treatment Market (2018-2034) by Treatment Type
- 16.3.1 Market Overview
- 16.3.2 Antiviral Drugs
- 16.3.3 Immunosuppressants
- 16.3.4 Vaccines
- 16.3.5 Corticosteroids
- 16.3.6 Immunoglobins
- 16.3.7 Targeted Therapy
- 16.3.8 Chemotherapy
- 16.3.9 Others
- 16.4 India Liver Disease Treatment Market (2018-2034) by Disease Type
- 16.4.1 Market Overview
- 16.4.2 Hepatitis
- 16.4.3 Autoimmune Diseases
- 16.4.4 Non-alcoholic fatty Liver Disease
- 16.4.5 Cancer
- 16.4.6 Others
- 16.5 India Liver Disease Treatment Market (2018-2034) by End User
- 16.5.1 Market Overview
- 16.5.2 Hospital and Clinics
- 16.5.3 Diagnostic Centers
- 16.5.4 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 Japan PMDA
- 17.5 India CDSCO
- 17.6 Others
- 18 Patent Analysis
- 18.1 Analysis by Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 19 Clinical Trials Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Grants Analysis
- 20.1 Analysis by Year
- 20.2 Analysis by Amount Awarded
- 20.3 Analysis by Issuing Authority
- 20.4 Analysis by Grant Application
- 20.5 Analysis by Funding Institute
- 20.6 Analysis by NIH Departments
- 20.7 Analysis by Recipient Organization
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Treatment Type of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Strategic Initiatives
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Treatment Type of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share by Top 5 Companies
- 23.2 Abbott Laboratories
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Company News and Development
- 23.2.5 Certifications
- 23.3 Astellas Pharma Inc.
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Company News and Development
- 23.3.5 Certifications
- 23.4 Bristol- Myers Squibb Company
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Company News and Development
- 23.4.5 Certifications
- 23.5 Gilead Sciences
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Company News and Development
- 23.5.5 Certifications
- 23.6 GlaxoSmithKline PLC
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Company News and Development
- 23.6.5 Certifications
- 23.7 F. Hoffmann-La Roche Ltd.
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Company News and Development
- 23.7.5 Certifications
- 23.8 Merck & Co., Inc.
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Company News and Development
- 23.8.5 Certifications
- 23.9 Novartis AG
- 23.9.1 Financial Analysis
- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Company News and Development
- 23.9.5 Certifications
- 23.10 Sanofi AG
- 23.10.1 Financial Analysis
- 23.10.2 Product Portfolio
- 23.10.3 Demographic Reach and Achievements
- 23.10.4 Company News and Development
- 23.10.5 Certifications
- 23.11 AbbVie Inc.
- 23.11.1 Financial Analysis
- 23.11.2 Product Portfolio
- 23.11.3 Demographic Reach and Achievements
- 23.11.4 Company News and Development
- 23.11.5 Certifications
- 23.12 Pfizer Inc.
- 23.12.1 Financial Analysis
- 23.12.2 Product Portfolio
- 23.12.3 Demographic Reach and Achievements
- 23.12.4 Company News and Development
- 23.12.5 Certifications
- 24 Liver Disease Treatment Treatment Drugs - Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
